| Oct 23 |
Cellectis Presents New Gene-Editing Breakthroughs
|
| Sep 17 |
Cibus announces proposed public offering of Class A common stock
|
| Sep 3 |
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
|
| Aug 26 |
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
|
| Aug 7 |
Cellectis names Adrian Kilcoyne as chief medical officer
|
| Aug 7 |
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
|
| Aug 6 |
Cellectis GAAP EPS of -$0.28 beats by $0.02, revenue of $9.5M beats by $5.77M
|
| Aug 6 |
Cellectis Provides Financial Results for the Second Quarter 2024
|
| Aug 2 |
Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia
|
| Aug 1 |
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
|
